Its active substance, methotrexate, is an antimetabolite that alters folate-dependent cell growth and reduces abnormal immune activity. Oral tablets are taken under an individual treatment plan, with careful monitoring for blood, liver and kidney changes.[1]
Methotrexate is used for severe inflammatory conditions such as rheumatoid arthritis and psoriasis, as well as selected cancers.
Methotrexate is used when inflammation is persistent, severe or likely to cause structural damage. Its clinical role includes autoimmune diseases, chronic inflammatory arthritis, psoriasis and selected cancers. The exact indication determines the schedule, laboratory monitoring and need for specialist supervision.
| Clinical setting | Therapeutic approach |
|---|---|
| Rheumatoid arthritis and related autoimmune disease | Low-dose Methotrexate, commonly administered once weekly, to suppress persistent immune inflammation |
| Psoriasis and severe inflammatory skin disease | Weekly treatment when systemic therapy is clinically appropriate |
| Cancer treatments | Specialist high-dose or protocol-specific therapy, sometimes with folinic acid rescue and hospital monitoring |
Methotrexate remains a cornerstone DMARD for rheumatoid arthritis because it can reduce synovial inflammation and slow disease progression. NICE guidance places Methotrexate among the conventional DMARD options used early in rheumatoid arthritis treatment when clinically suitable.[3]
Methotrexate and psoriasis treatment require attention to liver health, alcohol intake, infection risk and other medicines. Dermatology teams may use it for severe psoriasis or psoriatic disease when topical treatment is inadequate.
Clinical literature described as Methotrexate in the Treatment of Autoimmune Diseases – Modern Concepts in Rheumatology, Dermatology and Gastroenterology reflects the broad specialist use of this active substance across inflammatory disorders. The spelling “Rheamatoid Arthritis” is sometimes seen in informal material, while the recognised clinical term is rheumatoid arthritis.
Methotrexate can take several weeks to produce a clear improvement. A lack of immediate symptom relief does not mean that the treatment has failed, while worsening symptoms or new systemic symptoms need prompt clinical assessment.
Methotrexate resembles folate, a vitamin required for producing DNA and RNA. It inhibits dihydrofolate reductase, an enzyme that helps convert folate into forms needed for cell replication. This reduces the supply of folate derivatives required by rapidly dividing cells.
At higher concentrations, Methotrexate interferes strongly with DNA synthesis and is used in selected cancer treatments. At the lower weekly doses used for inflammatory disease, its anti-inflammatory activity also involves increased extracellular adenosine and reduced activation of immune cells. This explains why the same active substance can be used in both oncology and autoimmune disease, while the treatment schedules remain very different.[2]
Dihydrofolate reductase supports the formation of tetrahydrofolate, which participates in building DNA bases. When Methotrexate blocks this pathway, cells have less capacity to replicate.
Rapidly dividing tissues can therefore be affected. Bone marrow, the lining of the mouth and digestive tract, skin and hair follicles may be vulnerable. The immune system is also altered, which contributes to the reduction in autoimmune inflammation but can increase susceptibility to infection.
The pharmacology is dose-dependent.
Methotrexate is not suitable for everyone. It is not for you if any of the following applies unless a specialist has explicitly established a different treatment plan:
People with previous hepatitis, tuberculosis exposure, recurrent infections, lung disease, diabetes or high alcohol intake may need additional assessment. Vaccination planning also matters because immune suppression can alter vaccine decisions.
Methotrexate can cause serious fetal harm. People who could become pregnant need reliable contraception during treatment and for the period specified by the prescribing specialist after the final dose. Men receiving Methotrexate should discuss family-planning advice because recommendations depend on indication and treatment protocol.
Methotrexate can cause unwanted effects because it influences immune activity and the growth of rapidly dividing cells. Common problems include nausea, reduced appetite, mouth soreness, tiredness, headache and mild hair thinning. Folic acid is often prescribed to improve tolerability, but it does not remove the need for blood monitoring.
Some adverse effects require urgent assessment. Methotrexate-associated hepatotoxicity may appear through abnormal liver blood tests before symptoms develop. Bone marrow suppression can lead to anaemia, low white-cell counts or low platelets, increasing the risk of infection, fatigue or bleeding.
Regular monitoring commonly includes a full blood count, liver function tests and kidney function tests. The schedule may be more frequent after starting treatment, increasing the dose or adding another medicine.
Risk can rise with heavy alcohol intake, pre-existing liver disease, obesity, diabetes, viral hepatitis and other hepatotoxic medicines. Cumulative exposure also matters in long-term therapy. The clinical topic Methotrexate and Hepatotoxicity in Rheamatoid Arthritis Patients discusses hepatotoxicity in people treated for rheumatoid arthritis, although clinical decisions rely on current blood results and the patient’s full history.
Contact the prescribing service promptly for yellowing of the skin or eyes, dark urine, persistent vomiting, severe abdominal pain or marked loss of appetite. A normal result from one blood test does not remove the need for future monitoring.
Methotrexate-related bone marrow suppression may present as unexplained bruising, bleeding, fever, sore throat, mouth ulcers or unusual fatigue. These symptoms can also indicate infection or another complication.
Fever with a sore throat, breathlessness or rapidly worsening weakness needs urgent medical attention. Do not wait for the next routine appointment if these symptoms develop.
Methotrexate tablets contain methotrexate, an antimetabolite and immunosuppressant. At lower doses, Methotrexate acts as a disease-modifying antirheumatic drug, or DMARD, rather than simply relieving pain. DMARDs change inflammatory disease activity over time, which helps protect joints and reduce flare frequency in suitable patients.
Methotrexate is prescribed in rheumatology, dermatology, gastroenterology and oncology. The dose, timing and monitoring plan differ substantially between these uses. Methotrexate tablets are taken by mouth; injectable methotrexate is a separate formulation and should not be substituted without a prescriber’s direction.
For rheumatoid arthritis and related autoimmune diseases, Methotrexate aims to reduce the immune-driven inflammation that damages joints. The benefit develops gradually, so treatment is usually assessed over several weeks rather than after a single tablet.
Methotrexate is a potent systemic treatment. It requires a clear weekly schedule for many inflammatory conditions, regular blood tests and careful review of other medicines.
For inflammatory conditions, Methotrexate tablets are usually taken once weekly on the same day. They must not be taken daily unless a specialist oncology protocol explicitly requires daily administration in a controlled setting. Accidental daily use has caused fatal overdoses, and UK safety communications have repeatedly highlighted this risk.
The dose is decided individually, taking age, other medicines and health conditions into account. The prescriber may adjust the dose after reviewing disease response, full blood count, liver tests and kidney function.
Subcutaneous methotrexate may be used when oral treatment is poorly tolerated or absorption is a concern. High-dose Methotrexate belongs to specialist oncology protocols and may involve intravenous treatment, hydration, urine monitoring and folinic acid rescue. High-dose treatment is not a routine substitute for oral weekly treatment.
The required amount is not selected from a general list; it is prescribed according to the disease, response and laboratory results.
The most suitable treatment depends on the disease, previous response, pregnancy plans, infection risk, liver function and other medicines. Methotrexate is often selected because it has experience across several inflammatory conditions and can be combined with other disease-modifying treatments under monitoring.
| Treatment category | Main pharmacological distinction |
|---|---|
| Methotrexate | Antimetabolite with anti-inflammatory and immunosuppressive effects; commonly scheduled weekly for inflammatory disease |
| Other conventional DMARDs | Different immune pathways, with their own monitoring requirements and tolerability profiles |
| Biologic or targeted DMARDs | More selective immune targets; usually considered when conventional DMARD treatment is insufficient or unsuitable |
Methotrexate may be preferred when a conventional DMARD is appropriate and the patient can follow the monitoring plan. A biologic or targeted treatment may be considered when disease control remains inadequate, though these options have distinct infection and screening considerations.
The main limitation is its narrow margin for dosing errors. It can also cause liver toxicity, cytopenias, mouth ulcers, nausea and infection-related complications. The choice is based on the person’s clinical profile, not on symptom severity alone.
Several avoidable errors repeatedly lead to treatment problems:
A small practical safeguard helps: write the weekly day on a calendar and record each dose immediately after taking it. Do not rely on memory when treatment continues for months.
In clinical practice, doctors usually describe Methotrexate as a treatment that rewards routine. The weekly day, laboratory schedule and medication list matter as much as the tablet itself.
A rheumatology team generally expects symptom improvement to build gradually. The first assessment may focus on tolerability and early laboratory results, while later reviews consider joint swelling, morning stiffness, physical function and disease activity.
The most useful clinical distinction is between a predictable mild effect and a warning sign. Brief nausea after a dose may be manageable, while fever, mouth ulcers, bruising or breathlessness can signal toxicity and need prompt action.
Patients sometimes stop Methotrexate after a week because pain has not improved. That decision can remove a potentially useful DMARD before it has had time to work. The opposite mistake is continuing through symptoms of toxicity without reporting them. A written dosing plan helps patients distinguish expected treatment effects from warning signs. The prescribing team can adjust the plan when adverse effects or laboratory changes appear.
Alcohol can add to the risk of liver injury during Methotrexate treatment, so UK clinical practice generally recommends keeping intake low or avoiding it. The MHRA highlighted liver and dosing safety concerns in its methotrexate safety communications in 2019. Individual advice depends on liver tests, the indication, alcohol intake and other medicines.
Older adults can receive Methotrexate when kidney function, liver function, blood counts and concurrent medicines have been assessed. NHS and MHRA prescribing practice in 2025 places strong emphasis on monitoring because age-related reduction in kidney clearance can increase toxicity. A lower starting dose or closer blood-test schedule may be selected for some people.
Inflammatory diseases often require Methotrexate for months or years when it controls disease activity and monitoring remains satisfactory. NICE rheumatoid arthritis guidance updated in 2025 supports continuing a DMARD when it provides benefit and remains tolerated. Treatment may be reduced or stopped when disease control is sustained, but that decision should follow a planned review rather than abrupt self-discontinuation.
Pregnancy is a clear condition in which Methotrexate is generally contraindicated because it can cause fetal harm. The EMA Summary of Product Characteristics for methotrexate, published in 2024, also emphasises reproductive toxicity and the need for appropriate contraception. Severe liver disease, significant blood-count abnormalities, serious infection and severe kidney impairment can also rule out treatment or require specialist alternatives.
Methotrexate may cause dizziness, tiredness, headache, blurred vision or other symptoms that can impair driving or machinery work in some people. MHRA safety guidance in 2025 recommends avoiding these activities if symptoms affect alertness, coordination or vision. If the weekly dose repeatedly causes impairment, the treatment team can review timing, folate supplementation and other medicines.
Methotrexate is an antimetabolite that interferes with folate-dependent pathways and also reduces immune-cell activity through anti-inflammatory mechanisms. Sulfasalazine, a commonly considered conventional DMARD, acts through different immunomodulatory pathways and is not a folate antagonist. NICE guidance from 2025 treats these medicines as separate DMARD options, with the choice shaped by disease pattern, pregnancy plans, comorbidities and monitoring needs.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took Methotrexate tablets once a week for inflammatory arthritis. After several weeks, my hands were less stiff in the mornings and everyday tasks became easier. I was pleased that the improvement felt steady rather than sudden.
Methotrexate reduced the swelling in my joints, but the first weeks were slower than I expected and I felt mildly queasy after the weekly dose. Taking it with a simple routine helped, although the regular blood tests were an extra appointment to remember.
My psoriasis became much calmer after the treatment had time to work. I kept the weekly dose on the same evening and found that the routine fitted around work. The improvement was clear enough for me to continue the plan.
Methotrexate helped reduce the flare pattern I had been dealing with for months. I used a phone calendar for the weekly day and did not miss the monitoring appointments. The treatment required organisation, but the change in symptoms was worthwhile.
